STOCK TITAN

Interpace Biosciences Announces Third Quarter 2026 Financial and Business Results

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Interpace Biosciences (IDXG) reported third-quarter 2026 revenue of $10.4 million, up 18% from the prior-year quarter. Thyroid test volume rose 7%, and average thyroid revenue per test increased 11%. Gross margin reached 69%, versus 62%. Continuing operations recorded a $1.5 million loss, versus $1.0 million income, with stock compensation and non-recurring legal expenses contributing to costs. Adjusted EBITDA, an adjusted earnings measure, rose to $2.1 million from $1.3 million.

Nine-month revenue was $28.5 million, down from $29.5 million but up 13% against the thyroid-only pro forma comparison excluding discontinued PancraGEN operations. Operating cash flow fell to $1.351 million from $3.693 million. The balance sheet remained debt-free. Pancreatic cancer panel validation is underway; the company plans clinical studies across 2026–2027 and expects no program revenue in either year.

Loading...
Loading translation...
15 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 18 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointQ3 revenue increased 18% to $10.4 million from $8.8 million a year earlier.
  • Moderate pointQ3 gross margin expanded to 69% from 62% a year earlier.
  • Moderate pointQ3 adjusted EBITDA increased to $2.1 million from $1.3 million; margin reached approximately 20% versus approximately 14%.
  • Moderate pointTrailing twelve-month thyroid revenue reached $38.0 million, up approximately 13% against the comparable pro forma period.
  • Minor pointQ3 thyroid test volume increased 7% year over year.
10 minor points
  • Minor pointQ3 average thyroid revenue per test increased 11%.
  • Minor pointNine-month gross margin reached 66%, versus 61% reported and 59% pro forma a year earlier.
  • Minor pointNine-month adjusted EBITDA reached $4.4 million, or 15%, versus $3.7 million, or 13%, a year earlier.
  • Minor pointTrailing twelve-month thyroid test volume increased approximately 9%.
  • Minor pointCash increased to $2.929 million at September 30, 2026, from $2.505 million at December 31, 2025.
  • Minor point. Forward-looking: it has not happened yet and may not happen.The debt-free balance sheet supports investment in laboratory automation, AI-enabled productivity initiatives and research, the company said.
  • Minor pointAverage thyroid test turnaround time improved approximately 11% in the first nine months versus the prior-year period.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Pancreatic panel analytical validation is underway; clinical validation and utility studies are planned across 2026 and 2027.
  • Minor pointNine-month sales and marketing expense fell to $7.088 million from $7.811 million a year earlier.
  • Minor pointNine-month research and development expense fell to $461,000 from $500,000 a year earlier.

Negative

  • Moderate pointQ3 operating results fell to a $2.400 million loss from $1.145 million income a year earlier.
  • Moderate pointQ3 stock-based compensation rose to $3.993 million from $7,000 a year earlier.
  • Moderate pointNine-month revenue fell to $28.5 million from $29.5 million, but rose 13% against the thyroid-only pro forma comparison.
  • Moderate pointNine-month operating results fell to a $954,000 loss from $2.507 million income a year earlier.
  • Moderate pointNine-month operating cash flow fell to $1.351 million from $3.693 million a year earlier.
  • Moderate pointCurrent liabilities rose to $6.438 million at September 30, 2026, from $5.103 million at December 31, 2025.
12 minor points
  • Minor pointQ3 continuing operations recorded a $1.501 million loss, versus $1.011 million income a year earlier.
  • Minor pointQ3 net results fell to a $1.610 million loss from $911,000 income a year earlier.
  • Minor pointQ3 diluted results fell to a $0.28 loss per share from $0.16 income a year earlier.
  • Minor pointQ3 non-recurring legal expenses were $234,000, versus none a year earlier.
  • Minor pointQ3 sales and marketing expense rose to $2.704 million from $2.087 million a year earlier.
  • Minor pointQ3 research and development expense rose to $160,000 from $150,000 a year earlier.
  • Minor pointQ3 cash collections fell to $9.1 million from $10.0 million a year earlier.
  • Minor pointNine-month continuing operations recorded a $404,000 loss, versus $2.232 million reported and $1.008 million pro forma income.
  • Minor pointNine-month net results fell to a $731,000 loss from $1.918 million income a year earlier.
  • Minor pointNine-month diluted results fell to a $0.14 loss per share from $0.35 income a year earlier.
  • Minor pointNine-month investing cash outflow increased to $567,000 from $318,000 a year earlier.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Pancreatic cancer program revenue is not expected in 2026 or 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
  • Q3 Revenue of $10.4 million
  • Q3 Thyroid volume year-over-year increase of 7%
  • Q3 Thyroid revenue year-over-year increase of 18%
  • Trailing twelve-month thyroid revenue of $38.0 million, an increase of 13% on a comparable thyroid-only basis

PARSIPPANY, NJ, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCID: IDXG) today announced financial results for the third quarter ended September 30, 2026 and provided a business and financial update.

Interpace generated Q3 2026 revenue of $10.4 million, up 18% year-over-year, a loss from continuing operations of $1.5 million compared to income from continuing operations of $1.0 million in the prior year, and produced Adjusted EBITDA of $2.1 million, or 20% of revenue. The loss from continuing operations of $1.5 million included approximately $4.1 million of non-recurring stock compensation costs and non-recurring legal expenses.

As previously disclosed, the Company discontinued its PancraGEN® pancreatic testing business in May 2025 and now operates as a thyroid-only molecular diagnostics company. Prior-year reported results therefore include PancraGEN revenue and related costs, while the Company’s current-year results do not. Reported year-over-year comparisons for the nine-month period are affected by this change, and the Pro Forma prior-year results presented below exclude PancraGEN in order to show the underlying thyroid business on a consistent basis. Beginning with the third quarter of 2026, reported year-over-year comparisons will be presented on a directly comparable thyroid-only basis, as the prior-year comparative periods no longer include PancraGEN.

"The Company continued to convert revenue growth into margin expansion in the third quarter, reflecting the operating leverage we have built into the business," said Chris McCarthy, Chief Financial Officer. "Gross margin expanded to 69% in Q3 2026, up from 62% in Q3 2025 and 63% on a Pro Forma basis, supported by an 11% increase in average thyroid revenue per test and continued efficiency gains in our laboratory. That gross margin expansion carried through to the bottom line: Adjusted EBITDA margin improved to 20% from 14% in the prior year quarter and 17% on a Pro Forma basis, with Adjusted EBITDA increasing to $2.1 million from $1.3 million. Year-to-date, gross margin has expanded to 66% from 59%, and Adjusted EBITDA margin to 15% from 10%, compared to the prior year period on a Pro Forma basis. Q3 2026 revenue grew 18% to $10.4 million, or 15% on a Pro Forma basis, on 7% growth in thyroid test volume. These results reflect steady execution across our commercial and operations teams, and the clinical value physicians continue to see in ThyGeNEXT® and ThyraMIR®v2."

McCarthy added, “Our debt-free balance sheet continues to support meaningful investment in laboratory automation, AI-enabled productivity initiatives across our workflow, and research and development to advance our pipeline. Those investments are already showing up in our laboratory, where average ThyGeNEXT® and ThyraMIR®v2 turnaround time improved approximately 11% in the first nine months of 2026 compared to the prior year period. We are scaling operating leverage in line with volume growth without a corresponding increase in headcount, which we expect will support continued margin expansion.”

“The third quarter demonstrates the durability of the business we built through last year’s transition and the operating discipline we will carry through the remainder of 2026 and into 2027,” said Tom Burnell, President and CEO. “We see the same characteristics in Q3 2026 that defined our 2025 performance — disciplined execution, expanding clinical adoption, and a steady cadence of operational improvement. We continue to believe our combination approach — ThyGeNEXT® for mutation detection and ThyraMIR®v2 for microRNA pathway insights — gives physicians the confidence and clarity they need to make informed patient-management decisions.”

All share and per share numbers in this release give effect to the one-for-five reverse stock split effected on August 27, 2026.

Pancreatic Cancer Program Update

Interpace is seeking to extend the next-generation sequencing and microRNA technology platforms behind ThyGeNEXT® and ThyraMIR®v2 into pancreatic cancer. The program design includes an extensive genomic panel and proprietary microRNA classification aligned with National Comprehensive Cancer Network (NCCN) guidelines. Together, these technologies are intended to provide decision-making support to clinicians, including medical oncologists, for pancreatic cancer detection, classification, and neoadjuvant treatment selection. Analytical validation of the panel design is underway, with clinical validation and utility studies planned across 2026 and 2027, and reimbursement and launch activities to follow. This new product is in development, not yet available for clinical use, and has not been cleared or approved by the U.S. Food and Drug Administration. There can be no assurance that development will be completed on the anticipated timeline or at all, and the Company does not expect the program to contribute revenue in 2026 or 2027.

Third Quarter 2026 Financial Performance

For the Third Quarter of 2026 as Compared to the Third Quarter of 2025:

  • Revenue was $10.4 million, an increase of 18% from $8.8 million for the prior year quarter.
  • Gross Profit percentage was 69% compared to 62% for the prior year quarter.
  • Operating loss was $2.4 million versus operating income of $1.1 million in the prior year quarter.
  • Loss from continuing operations was $1.5 million versus income from continuing operations of $1.0 million in the prior year quarter.
  • Loss from continuing operations for the third quarter of 2026 included approximately $4.1 million of non-recurring stock compensation costs and non-recurring legal expenses. These charges are excluded from Adjusted EBITDA.
  • Adjusted EBITDA was $2.1 million versus $1.3 million in the prior year quarter.
  • Adjusted EBITDA margin was approximately 20% compared to approximately 14% for the prior year quarter.
  • Q3 2026 cash collections totaled $9.1 million compared to $10.0 million in the prior year quarter.

Year-to-Date and Trailing Twelve-Month Performance

  • Revenue for the nine months ended September 30, 2026 was $28.5 million, a decrease from $29.5 million for the prior year period and an increase of 13% from $25.3 million for the prior year period Pro Forma.
  • Gross Profit percentage for the nine months ended September 30, 2026 was 66% compared to 61% for the prior year period and 59% for the prior year period Pro Forma.
  • Loss from continuing operations for the nine months ended September 30, 2026 was $0.4 million compared to income from continuing operations of $2.2 million for the prior year period and $1.0 million for the prior year period Pro Forma, and included approximately $4.4 million of non-recurring stock compensation costs and non-recurring legal expenses.
  • Adjusted EBITDA for the nine months ended September 30, 2026 was $4.4 million, or 15% of revenue, compared to $3.7 million, or 13% of revenue for the prior year period and $2.5 million, or 10% of revenue, for the prior year period Pro Forma.
  • On a trailing twelve-month basis, thyroid revenue was $38.0 million, an increase of approximately 13% over the comparable prior twelve-month period Pro Forma, on trailing twelve-month thyroid test volume growth of approximately 9%.

Management uses a non-GAAP Pro Forma income statement to help evaluate the results of our performance. The Pro Forma income statement for 2025 reflects the Company’s current business structure as a thyroid-only diagnostics testing company and excludes revenue and related costs from PancraGEN, which was discontinued in May 2025. These adjustments are presented for comparability purposes only and do not represent GAAP financial measures. Investors should review GAAP results alongside these pro forma figures for a complete understanding of performance. A reconciliation of GAAP and these pro forma figures is presented below.

About Interpace Biosciences

Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests and bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has two commercialized molecular tests: ThyGeNEXT® for the diagnosis of thyroid cancer from thyroid nodules utilizing a next-generation sequencing assay and ThyraMIR®v2, used in combination with ThyGeNEXT®, for the diagnosis of thyroid cancer utilizing a proprietary microRNA pairwise expression profiler along with algorithmic classification.

For more information, please visit Interpace Biosciences’ website at www.interpace.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company’s future financial and operating performance. The Company has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from those expressed or implied by any forward-looking statements, including, but not limited to, the possibility that the Company’s estimates of future revenue, cash flows, and net income, as well as Pro Forma financial results and adjusted EBITDA may prove to be materially inaccurate, the Company’s prior history of operating losses, the Company’s ability to adequately finance its business and seek alternative sources of financing, the Company’s dependence on sales and reimbursements from its clinical services, the Company’s ability to retain or secure reimbursement including its reliance on third parties to process and transmit claims to payers and the adverse impact of any delay, data loss, or other disruption in processing or transmitting such claims, and the Company’s revenue recognition being based in part on estimates for future collections which estimates may prove to be incorrect.

Additionally, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contacts

Investor Relations
Interpace Biosciences, Inc.
(855)-776-6419
Info@Interpace.com

INTERPACE BIOSCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)

  Three Months Ended  Nine Months Ended 
  September 30,  September 30, 
  2026  2025  2026  2025 
  (unaudited)  (unaudited) 
             
Revenue, net $10,373  $8,756  $28,537  $29,504 
Cost of revenue  3,193   3,317   9,799   11,418 
Gross Profit  7,180   5,439   18,738   18,086 
                 
Sales and marketing  2,704   2,087   7,088   7,811 
Research and development  160   150   461   500 
General and administrative  6,716   2,057   12,143   7,268 
Total operating expenses  9,580   4,294   19,692   15,579 
                 
Operating (loss) income  (2,400)  1,145   (954)  2,507 
Note payable interest expense  -   (30)  -   (156)
Other income (expense), net  15   (115)  33   (112)
(Loss) income from continuing operations before tax  (2,385)  1,000   (921)  2,239 
Benefit (provision) for income taxes  (884)  (11)  (517)  7 
(Loss) income from continuing operations  (1,501)  1,011   (404)  2,232 
                 
Loss from discontinued operations, net of tax  (109)  (100)  (327)  (314)
                 
Net (loss) income $(1,610) $911   (731)  1,918 
                 
Basic income (loss) per share of common stock:                
From continuing operations $(0.26) $1.14  $(0.08) $2.52 
From discontinued operations  (0.02)  (0.11)  (0.06)  (0.35)
Net income (loss) per basic share of common stock $(0.28) $1.03  $(0.14) $2.17 
                 
Diluted income (loss) per share of common stock:                
From continuing operations $(0.26) $0.18  $(0.08) $0.40 
From discontinued operations  (0.02)  (0.02)  (0.06)  (0.06)
Net income (loss) per diluted share of common stock $(0.28) $0.16  $(0.14) $0.35 
                 
Weighted average number of common shares and                
common share equivalents outstanding:                
Basic  5,705   885   5,210   885 
Diluted  5,705   5,539   5,210   5,539 


Selected Balance Sheet Data

($ in thousands)

  September 30,  December 31, 
  2026  2025 
       
Cash and cash equivalents $2,929  $2,505 
         
Total current assets  13,286   9,900 
Total current liabilities  6,438   5,103 
         
Total assets  37,468   33,838 
Total liabilities  12,777   11,475 
Total stockholders' equity  24,691   22,363 


Selected Cash Flow Data 

($ in thousands)

  For the Nine Months Ended 
  September 30, 
  2026  2025 
       
Net (loss) income $(731) $1,918 
         
Net cash provided by operating activities $1,351  $3,693 
Net cash used in investing activities  (567)  (318)
Net cash used in financing activities  (360)  (3,413)
Change in cash and cash equivalents  424   (38)
Cash and cash equivalents – beginning  2,505   1,461 
Cash and cash equivalents – ending $2,929  $1,423 


Reconciliation of Pro Forma (Unaudited)

(in thousands, except per share data)

  Nine Months Ended September 30, 2025 
     PancraGEN    
  As Reported  Direct Costs*  Pro Forma 
          
Revenue, net $29,504  $4,193  $25,311 
Cost of revenue  11,418   1,023   10,395 
Gross Profit  18,086   3,170   14,916 
             
Sales and marketing  7,811   1,653   6,158 
Research and development  500   100   400 
General and administrative  7,268   193   7,075 
Total operating expenses  15,579   1,946   13,633 
             
Operating income  2,507   1,224   1,283 
             
Note payable interest  (156)  -   (156)
Other expense, net  (112)  -   (112)
Income from continuing operations before tax  2,239   1,224   1,015 
Provision for income taxes  7   -   7 
 Income from continuing operations  2,232   1,224   1,008 
             
Loss from discontinued operations, net of tax  (314)  -   (314)
             
Net income $1,918  $1,224  $694 
             
             
Basic income (loss) per share of common stock:            
From continuing operations $2.52  $1.38  $1.14 
From discontinued operations  (0.35)  -   (0.35)
Net income (loss) per basic share of common stock $2.17  $1.38  $0.78 
             
Diluted income (loss) per share of common stock:            
From continuing operations $0.40  $0.22  $0.18 
From discontinued operations  (0.06)  -   (0.06)
Net income (loss) per diluted share of common stock $0.35  $0.22  $0.13 
             
Weighted average number of common shares and            
common share equivalents outstanding:            
Basic  885   885   885 
Diluted  5,539   5,539   5,539 


* PancraGEN Direct Costs represent only direct costs associated with the operations of PancraGEN testing, with no allocations or estimates of corporate, shared, or overhead expenses included.

Reconciliation of Adjusted EBITDA (Unaudited)
($ in thousands)

  Three Months Ended  Nine Months Ended 
  September 30,  September 30, 
  2026  2025  2026  2025 
(Loss) income from continuing operations (GAAP Basis) $(1,501) $1,011  $(404) $2,232 
Depreciation and amortization  141   111   386   307 
Stock-based compensation  3,993   7   4,001   31 
Non-recurring legal expenses  234   -   614   - 
Severance & related expense  -   -   -   692 
Asset impairment - lab supplies  -   -   -   198 
Loss on sale of asset  104   -   104   - 
Lab supplies write-off  -   -   217   - 
Income tax (benefit) expense  (884)  (11)  (517)  7 
Note payable interest  -   30   -   156 
Other income/expense, net  (15)  10   (33)  25 
Change in fair value of note payable  -   105   -   87 
Adjusted EBITDA $2,072  $1,263  $4,368  $3,735 


Non-GAAP Financial Measures

In addition to the United States generally accepted accounting principles, or GAAP, results provided throughout this document, we have provided certain non-GAAP financial measures to help evaluate the results of our performance. We believe that these non-GAAP financial measures, when presented in conjunction with comparable GAAP financial measures, are useful to both management and investors in analyzing our ongoing business and operating performance. We believe that providing the non-GAAP information to investors, in addition to the GAAP presentation, allows investors to view our financial results in the way that management views financial results.

In this document, we discuss Adjusted EBITDA, a non-GAAP financial measure. Adjusted EBITDA is a metric used by management to measure cash flow of the ongoing business. Adjusted EBITDA is defined as income or loss from continuing operations, plus depreciation and amortization, non-cash stock-based compensation, severance expense, asset impairment-lab supplies, non-recurring legal expenses, interest and taxes, and other non-cash expenses including change in fair values of notes payable. The table above includes a reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure.


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Interpace Biosciences' Q3 2026 revenue and earnings?

Interpace reported $10.4 million revenue, up 18% year over year, and a $1.501 million loss from continuing operations, versus $1.011 million income a year earlier. Adjusted EBITDA increased to $2.1 million from $1.3 million.

How does Interpace calculate its 2025 thyroid-only pro forma comparison?

The 2025 pro forma comparison excludes PancraGEN revenue and related direct costs following its discontinuation in May 2025. The excluded costs contain no allocations or estimates of corporate, shared or overhead expenses. These comparisons are non-GAAP financial measures.

When did Interpace Biosciences' reverse stock split take effect?

Interpace's one-for-five reverse stock split took effect on August 27, 2026. All share and per-share figures in the financial results reflect that split.

Keep reading